Antiretroviral drugs and therapy (ART)

Now is a critical time to ensure widest possible access to ART: a landmark scientific breakthrough in 2011 showed that treatment with antiretroviral medicines (ARVs) not only saves lives, but can also stop HIV from being transmitted by up to 96%.

This document highlights key issues that confront the global community, policy-makers and national programme planners as they seek to make optimal use of antiretroviral drugs (ARVs) as part of the broader response to HIV.

At the end of 2011, more than 8 million people were receiving antiretroviral therapy in low- and middle-income countries, a dramatic 26-fold increase from December 2003. Although it can be minimized, some degree of HIV drug resistance is anticipated to emerge among people on treatment even when appropriate antiretroviral therapy is provided and high levels of adherence are achieved.

This paper documents the recent developments, opportunities and challenges in intellectual property rights and access to affordable medicines in China.

This report summarises the results of qualitative research that was conducted to better understand reasons for initiating, continuing and ceasing treatment among PLHIV in the Pacific Islands.

This issue of Bite Size Briefs is a summary of the Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations, which was published by the World Health Organization (WHO) in July 2014.

In this report we examine global trends in ARV prices and assess how WHO treatment guidelines have influenced the uptake of different ARV formulations.

The purpose of this survey is to calculate (a) a nationally representative prevalence estimate of HIVDR among all ART initiators, and (b) a nationally representative prevalence estimate of HIVDR among initiators without prior exposure to ARV drugs.

This document provides Cohort analysis for patients who started ART in 2013 (12 months), Cohort analysis for patients who started ART in 2012 (24 months) and Cohort analysis for patients who started ART in 2009 (60 months).

Developed by Southern African AIDS Trust, with the support of WHO and UNAIDS, the summary of the the WHO’s New Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection is now available.